Market Overview

UPDATE: Stifel Nicolaus Raises PT to $6.51 on Boston Scientific Corporation S-ICD Checks

Related BSX
US Stock Futures Down Ahead Of Fed Minutes
Boston Scientific Announces Additional Investment And Right To Acquire MValve Technologies

Stifel Nicolaus reiterated Boston Scientific Corporation (NYSE: BSX) at Buy and increased the price target from $6.50 to $7.00.

Stifel Nicolaus noted, "Our recent physician checks with U.S. and EU electrophysiologists (EPs) reinforce our thesis that ultimately S-ICDs could represent 10% or more of overall ICD implants over time, if ongoing registry trials continue to suggest comparable performance versus traditional ICDs. We suspect this 10% penetration is greater than generally expected. These checks also reinforced our view that the S-ICD could potentially help re-invigorate BSX's beleaguered ICD franchise (~19% of 2012 estimated sales)."

Boston Scientific Corporation closed at $6.51 on Tuesday.

Latest Ratings for BSX

Oct 2015Raymond JamesDowngradesOutperformStrong Buy
Sep 2015NeedhamUpgradesBuy
Sep 2015UBSInitiates Coverage onBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (BSX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters